Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 3/20 | 0.32 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641032 | 0.80 | HTR2C (0.43) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16516779 | 0.77 | CYP3A4 (0.37) | CA1CA2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL645528 | 0.77 | ALDH1A1 (0.45) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8026248 | 0.76 | ENPP2 (0.41) | ENPP2CA1CA2TUBB4ATUBB | |
| SCHEMBL7052653 | 0.73 | HTR2C (0.46) | CA1CA2CA9CA12 | |
| SCHEMBL8796050 | 0.71 | CYP3A4 (0.35) | CYP3A4CYP2C9CYP2C19SCN9ATUBB4A | |
| SCHEMBL404823 | 0.71 | RARA (0.51) | CTSDBACE1BACE2PKMCNR2 | |
| SCHEMBL31482681 | 0.71 | RARA (0.51) | CTSDBACE1BACE2PKMCNR2 | |
| SCHEMBL23114 | 0.69 | ENPP2 (0.52) | ENPP2CA1CA2CYP3A4CYP2C9 | |
| SCHEMBL3191612 | 0.69 | ALDH1A1 (0.53) | ENPP2CA1CA2CYP3A4TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139838-B1 | A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| US-20100160677-A1 | PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. | JSC GRINDEKS (LV) | 2010-06-24 | — | — | US | disclosed |
| EP-2139838-A2 | A PROCESS FOR THE PREPARATION OF 6-Ý3-(1-ADAMANTYL)-4-METHOXYPHENYL-2-NAPHTOIC ACID | Grindeks, a joint stock company (LV) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008080992-A3 | A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL-2-NAPHTOIC ACID | KALVINSH IVARS (LV) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008080992-A2 | A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL-2-NAPHTOIC ACID | KALVINSH IVARS (LV) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160677-A1 | PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. | ME1, CD274, PDCD1LG2 | ENPP2 2737/4885CA1 714/4885CA2 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.